Clinical Trial

A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 10, 2022 (before its estimated August 3, 2025 completion). Its status may not reflect the trial's current state.
Summary
A Exploratory Study of drug combination (zoledronic acid/interleukin 2) that specifically amplifies Vγ2Vδ2 T cells in combination with anti-tuberculosis chemotherapy for the treatment of MDR-TB.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-08-05.
Trial Details
NCT Number NCT05493267
Lead Sponsor Shanghai Pulmonary Hospital, Shanghai, China
Collaborators: Shanghai Public Health Clinical Center, Huashan Hospital, No.85 Hospital, Changning, Shanghai, China
Conditions MDR-TB, Immunotherapy
Enrollment 30 participants
Start Date 2022-08-03
Primary Completion 2025-08-03 (estimated)
Study Completion 2027-08-03 (estimated)
Updated on ClinicalTrials.gov 2022-08-10